X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2019 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Aventis Pharma with STRIDES PHARMA SCIENCE - Equitymaster

Helping You Build Wealth With Honest Research
Since 1996. Try Now

  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

SANOFI INDIA vs STRIDES PHARMA SCIENCE - Comparison Results

SANOFI INDIA    Change

Sanofi India (the erstwhile Aventis Pharma), the 60% subsidiary of Sanofi-Aventis SA, France, is one of the largest pharma MNCs in India with a turnover of over Rs 13.2 bn in CY11. Domestic sales constituted 81% of total sales in CY11 and exports con... More

STRIDES PHARMA SCIENCE 
   Change

Strides Arcolab is an Indian pharmaceutical company headquartered at Bangalore. The company is primarily involved in two businesses notably the pharma business and the specialized sterile products business branded as Agila. This segment focuses large... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    SANOFI INDIA STRIDES PHARMA SCIENCE SANOFI INDIA/
STRIDES PHARMA SCIENCE
 
P/E (TTM) x 36.5 60.3 60.5% View Chart
P/BV x 6.9 1.0 675.0% View Chart
Dividend Yield % 0.6 0.5 115.8%  

Financials

 SANOFI INDIA   STRIDES PHARMA SCIENCE
EQUITY SHARE DATA
    SANOFI INDIA
Dec-17
STRIDES PHARMA SCIENCE
Mar-18
SANOFI INDIA/
STRIDES PHARMA SCIENCE
5-Yr Chart
Click to enlarge
High Rs4,9451,147 431.1%   
Low Rs3,901642 607.6%   
Sales per share (Unadj.) Rs1,081.8317.2 341.0%  
Earnings per share (Unadj.) Rs141.67.8 1,804.5%  
Cash flow per share (Unadj.) Rs185.925.1 742.1%  
Dividends per share (Unadj.) Rs33.002.00 1,650.0%  
Dividend yield (eoy) %0.70.2 333.7%  
Book value per share (Unadj.) Rs868.8274.3 316.8%  
Shares outstanding (eoy) m23.0389.50 25.7%   
Bonus/Rights/Conversions -ESOP-  
Price / Sales ratio x4.12.8 145.0%   
Avg P/E ratio x31.2114.0 27.4%  
P/CF ratio (eoy) x23.835.7 66.6%  
Price / Book Value ratio x5.13.3 156.1%  
Dividend payout %23.325.5 91.4%   
Avg Mkt Cap Rs m101,86280,058 127.2%   
No. of employees `0003.22.5 129.2%   
Total wages/salary Rs m3,6854,341 84.9%   
Avg. sales/employee Rs Th7,691.911,325.8 67.9%   
Avg. wages/employee Rs Th1,137.71,731.4 65.7%   
Avg. net profit/employee Rs Th1,006.5280.1 359.4%   
INCOME DATA
Net Sales Rs m24,91428,394 87.7%  
Other income Rs m807941 85.8%   
Total revenues Rs m25,72129,334 87.7%   
Gross profit Rs m5,3723,965 135.5%  
Depreciation Rs m1,0221,540 66.3%   
Interest Rs m111,962 0.6%   
Profit before tax Rs m5,1461,403 366.7%   
Minority Interest Rs m00-   
Prior Period Items Rs m0-168 0.0%   
Extraordinary Inc (Exp) Rs m0-436 0.0%   
Tax Rs m1,88697 1,938.3%   
Profit after tax Rs m3,260702 464.3%  
Gross profit margin %21.614.0 154.4%  
Effective tax rate %36.66.9 528.5%   
Net profit margin %13.12.5 529.2%  
BALANCE SHEET DATA
Current assets Rs m14,43224,836 58.1%   
Current liabilities Rs m6,01018,993 31.6%   
Net working cap to sales %33.820.6 164.3%  
Current ratio x2.41.3 183.6%  
Inventory Days Days6171 85.8%  
Debtors Days Days28113 25.1%  
Net fixed assets Rs m7,99134,289 23.3%   
Share capital Rs m230895 25.7%   
"Free" reserves Rs m19,77823,651 83.6%   
Net worth Rs m20,00824,546 81.5%   
Long term debt Rs m015,513 0.0%   
Total assets Rs m27,77065,437 42.4%  
Interest coverage x468.81.7 27,335.7%   
Debt to equity ratio x00.6 0.0%  
Sales to assets ratio x0.90.4 206.8%   
Return on assets %11.84.1 289.3%  
Return on equity %16.32.9 569.6%  
Return on capital %25.86.9 373.8%  
Exports to sales %00-   
Imports to sales %00-   
Exports (fob) Rs mNANA-   
Imports (cif) Rs mNANA-   
Fx inflow Rs m6,30615,697 40.2%   
Fx outflow Rs m5,257735 714.8%   
Net fx Rs m1,04914,962 7.0%   
CASH FLOW
From Operations Rs m4,3511,871 232.6%  
From Investments Rs m-7875,826 -13.5%  
From Financial Activity Rs m-1,884-10,157 18.5%  
Net Cashflow Rs m1,680-2,615 -64.2%  

Share Holding

Indian Promoters % 0.0 27.7 -  
Foreign collaborators % 60.4 0.0 -  
Indian inst/Mut Fund % 14.4 37.8 38.1%  
FIIs % 14.6 8.6 169.8%  
ADR/GDR % 0.0 0.0 -  
Free float % 10.5 25.9 40.5%  
Shareholders   15,184 56,241 27.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare SANOFI INDIA With:   MERCK LTD  STERLING BIOTECH  JUBILANT LIFE SCIENCES  AUROBINDO PHARMA  IPCA LABS  

Compare SANOFI INDIA With:   ACTAVIS (US)  MYLAN (US)  ADCOCK INGRAM (S. Africa)  TEVA PHARMA (Israel)  



Today's Market

Recapitalisation Package for PSBs: The Pros & Cons(Podcast)

Corporate governance issues with certain companies, uncertainty surrounding national elections and global issues like trade wars, Brexit, have taken a toll on the Indian markets.

Related Views on News

STRIDES PHARMA SCIENCE Announces Quarterly Results (3QFY19); Net Profit Down 27.5% (Quarterly Result Update)

Jan 30, 2019 | Updated on Jan 30, 2019

For the quarter ended December 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 316 m (down 27.5% YoY). Sales on the other hand came in at Rs 8 bn (up 6.1% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

STRIDES PHARMA SCIENCE 2017-18 Annual Report Analysis (Annual Result Update)

Dec 19, 2018 | Updated on Dec 19, 2018

Here's an analysis of the annual report of STRIDES PHARMA SCIENCE for 2017-18. It includes a full income statement, balance sheet and cash flow analysis of STRIDES PHARMA SCIENCE. Also includes updates on the valuation of STRIDES PHARMA SCIENCE.

STRIDES PHARMA SCIENCE Announces Quarterly Results (2QFY19); Net Profit Down 72.2% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, STRIDES PHARMA SCIENCE has posted a net profit of Rs 54 m (down 72.2% YoY). Sales on the other hand came in at Rs 7 bn (down 26.4% YoY). Read on for a complete analysis of STRIDES PHARMA SCIENCE's quarterly results.

SANOFI INDIA Announces Quarterly Results (2QFY19); Net Profit Up 2.5% (Quarterly Result Update)

Nov 6, 2018 | Updated on Nov 6, 2018

For the quarter ended September 2018, SANOFI INDIA has posted a net profit of Rs 1 bn (up 2.5% YoY). Sales on the other hand came in at Rs 7 bn (up 11.4% YoY). Read on for a complete analysis of SANOFI INDIA's quarterly results.

STRIDES SHASUN LTD Announces Quarterly Results (1QFY19); Net Profit Down 57.5% (Quarterly Result Update)

Aug 10, 2018 | Updated on Aug 10, 2018

For the quarter ended June 2018, STRIDES SHASUN LTD has posted a net profit of Rs 38 m (down 57.5% YoY). Sales on the other hand came in at Rs 7 bn (down 21.2% YoY). Read on for a complete analysis of STRIDES SHASUN LTD's quarterly results.

More Views on News

Most Popular

The One Real Estate Stock to Buy Now(The 5 Minute Wrapup)

Feb 13, 2019

The real estate sector is ready to make a comeback. This is the stock to consider buying.

Don't Be Afraid of the Market; Buy Stocks Like This One(The 5 Minute Wrapup)

Feb 14, 2019

During this tough period in the market, a contrarian approach holds huge potential upside for this Smart Money Secrets stock.

Small Caps Under Seige: Could This Be A Once-in-a-Decade Wealth Creating Opportunity?(Profit Hunter)

Feb 14, 2019

Don't let the dark clouds hovering over small caps scare you into hiding; it will rain gold as sentiments recover. Indeed, there is a blood bath. And if you are a first time investor, the correction is deep enough to scare you out of markets.

The 4-Point Plan to Accelerate India to a 10 Trillion Dollar Economy(The 5 Minute Wrapup)

Feb 12, 2019

Two questions I have been eagerly waiting to ask you ever since Budget 2019 was announced.

The Train to 'Small-Cap-Profits Land' is Back on the Station!(Profit Hunter)

Feb 15, 2019

Why its great news that prices for small caps over the last few days have been falling like there's no tomorrow.

More

Get the Indian Stock Market's
Most Profitable Ideas

How To Beat Sensex Guide 2019
Get our special report, How to Beat Sensex Nearly 3X Now!
We will never sell or rent your email id.
Please read our Terms

SANOFI INDIA SHARE PRICE


Feb 22, 2019 (Close)

TRACK SANOFI INDIA

  • Track your investment in SANOFI INDIA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

SANOFI INDIA 8-QTR ANALYSIS

COMPARE SANOFI INDIA WITH

MARKET STATS